Global biopharmaceutical company Ipsen has announced a significant investment of €27m to upgrade and expand manufacturing capabilities at its Blanchardstown site in Dublin. Ipsen has invested €52m already this year and has expanded its team in Ireland by more than 20% since 2019.
The investment will facilitate increased production of vital medical treatment that helps patients suffering from both niche cancers and rare diseases.
A spokesperson for Ipsen said that the company has expanded its team in Ireland by more than 20% since 2019, with 165 employees now working at the Blanchardstown site across research and development, manufacturing and commercial operations, delivering specialty care Active Pharmaceutical Ingredients (APIs) for patients with rare and underserved conditions.
The latest announcement builds on the company’s €25m investment earlier this year to scale its capacity in Ireland to deliver innovative medicines for patients across the world with rare and life-limiting medical conditions.
Manufacturing has commenced at the upgraded facility in Dublin in recent weeks with new equipment enabling more efficient and sustainable production processes – these will significantly increase Ipsen’s production of the active ingredient for one of its leading rare cancer treatments in 2022.
Tim Shanahan, head of Site in Dublin, said, “our dedicated employees here in Ireland are driven by a shared commitment to deliver life-changing care for patients with rare and underserved medical conditions. Our cumulative investment of €52m in Ipsen’s Irish manufacturing site this year will enable our team of 165 in Dublin to significantly scale its production of vital and innovative treatments as we move forward into 2022.”
“The Irish market plays a significant part in Ipsen’s international network and we are committed to continued improvement and growth of our activity here, with the constant goal of delivering better treatment for patients who deserve better care and quality of life.”
Source: Bank of Ireland